A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
Latest Information Update: 09 Dec 2025
At a glance
- Drugs Ecnoglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Sciwind Biosciences
Most Recent Events
- 09 Dec 2025 New trial record